Literature DB >> 9756773

gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae.

L M Weigel1, C D Steward, F C Tenover.   

Abstract

Fluoroquinolone resistance (FQ-R) in clinical isolates of Enterobacteriaceae species has been reported with increasing frequency in recent years. Two mechanisms of FQ-R have been identified in gram-negative organisms: mutations in DNA gyrase and reduced intracellular drug accumulation. A single point mutation in gyrA has been shown to reduce susceptibility to fluoroquinolones. To determine the extent of gyrA mutations associated with FQ-R in enteric bacteria, one set of oligonucleotide primers was selected from conserved sequences in the flanking regions of the quinolone resistance-determining regions (QRDR) of Escherichia coli and Klebsiella pneumoniae. This set of primers was used to amplify and sequence the QRDRs from 8 Enterobacteriaceae type strains and 60 fluoroquinolone-resistant clinical isolates of Citrobacter freundii, Enterobacter aerogenes, Enterobacter cloacae, E. coli, K. pneumoniae, Klebsiella oxytoca, Providencia stuartii, and Serratia marcescens. Although similarity of the nucleotide sequences of seven species ranged from 80.8 to 93.3%, when compared with that of E. coli, the amino acid sequences of the gyrA QRDR were highly conserved. Conservative amino acid substitutions were detected in the QRDRs of the susceptible type strains of C. freundii, E. aerogenes, K. oxytoca (Ser-83 to Thr), and P. stuartii (Asp-87 to Glu). Strains with ciprofloxacin MICs of >2 microg/ml expressed amino acid substitutions primarily at the Gly-81, Ser-83, or Asp-87 position. Fluoroquinolone MICs varied significantly for strains exhibiting identical gyrA mutations, indicating that alterations outside gyrA contribute to resistance. The type and position of amino acid alterations also differed among these six genera. High-level FQ-R frequently was associated with single gyrA mutations in all species of Enterobacteriaceae in this study except E. coli.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9756773      PMCID: PMC105915     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Mutations in the gyrA and parC genes associated with fluoroquinolone resistance in clinical isolates of Citrobacter freundii.

Authors:  Y Nishino; T Deguchi; M Yasuda; T Kawamura; M Nakano; E Kanematsu; S Ozeki; Y Kawada
Journal:  FEMS Microbiol Lett       Date:  1997-09-15       Impact factor: 2.742

Review 2.  Bacterial resistance to fluoroquinolones: mechanisms and patterns.

Authors:  D C Hooper
Journal:  Adv Exp Med Biol       Date:  1995       Impact factor: 2.622

3.  gyrA mutations in high-level fluoroquinolone-resistant clinical isolates of Escherichia coli.

Authors:  S Conrad; M Oethinger; K Kaifel; G Klotz; R Marre; W V Kern
Journal:  J Antimicrob Chemother       Date:  1996-09       Impact factor: 5.790

4.  gyrA mutations in quinolone-resistant isolates of the fish pathogen Aeromonas salmonicida.

Authors:  H Oppegaard; H Sørum
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

5.  Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in quinolone-resistant clinical isolates of Klebsiella pneumoniae.

Authors:  T Deguchi; A Fukuoka; M Yasuda; M Nakano; S Ozeki; E Kanematsu; Y Nishino; S Ishihara; Y Ban; Y Kawada
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

6.  Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro.

Authors:  J Tankovic; B Perichon; J Duval; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

7.  Ciprofloxacin-resistant Haemophilus influenzae strains possess mutations in analogous positions of GyrA and ParC.

Authors:  M Georgiou; R Muñoz; F Román; R Cantón; R Gómez-Lus; J Campos; A G De La Campa
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

8.  Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit.

Authors:  L Archibald; L Phillips; D Monnet; J E McGowan; F Tenover; R Gaynes
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

9.  Sequential mutations of gyrA in Escherichia coli associated with quinolone therapy.

Authors:  Q C Truong; S Ouabdesselam; D C Hooper; N J Moreau; C J Soussy
Journal:  J Antimicrob Chemother       Date:  1995-12       Impact factor: 5.790

10.  Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs.

Authors:  J Vila; J Ruiz; F Marco; A Barcelo; P Goñi; E Giralt; T Jimenez de Anta
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

View more
  81 in total

1.  Quinolone resistance-determining regions of gyrA and parC in Pasteurella multocida strains with different levels of nalidixic acid resistance.

Authors:  M Cárdenas; J Barbé; M Llagostera; E Miró; F Navarro; B Mirelis; G Prats; I Badiola
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

2.  The Red Menace: Emerging Issues in Antimicrobial Resistance in Gram-Negative Bacilli.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-10       Impact factor: 3.725

3.  Modification of outer membrane protein profile and evidence suggesting an active drug pump in Enterobacter aerogenes clinical strains.

Authors:  Stéphane Gayet; Renaud Chollet; Gérard Molle; Jean-Marie Pagès; Jacqueline Chevalier
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

4.  Changes in ciprofloxacin resistance levels in Enterobacter aerogenes isolates associated with variable expression of the aac(6')-Ib-cr gene.

Authors:  Elena Ruiz; Alain A Ocampo-Sosa; Julia Alcoba-Flórez; Elena Román; Guillaume Arlet; Carmen Torres; Luis Martínez-Martínez
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

5.  Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility.

Authors:  Oren Zimhony; Inna Chmelnitsky; Rita Bardenstein; Sorel Goland; Orly Hammer Muntz; Shiri Navon Venezia; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

6.  Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.

Authors:  Mario Tumbarello; Maurizio Sanguinetti; Eva Montuori; Enrico M Trecarichi; Brunella Posteraro; Barbara Fiori; Rita Citton; Tiziana D'Inzeo; Giovanni Fadda; Roberto Cauda; Teresa Spanu
Journal:  Antimicrob Agents Chemother       Date:  2007-03-26       Impact factor: 5.191

7.  Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinct selective pressures.

Authors:  L C McDonald; F J Chen; H J Lo; H C Yin; P L Lu; C H Huang; P Chen; T L Lauderdale; M Ho
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

Review 8.  Non-phenotypic tests to detect and characterize antibiotic resistance mechanisms in Enterobacteriaceae.

Authors:  Agnese Lupo; Krisztina M Papp-Wallace; Parham Sendi; Robert A Bonomo; Andrea Endimiani
Journal:  Diagn Microbiol Infect Dis       Date:  2013-10-03       Impact factor: 2.803

9.  DNA gyrase and topoisomerase IV mutations associated with fluoroquinolone resistance in Proteus mirabilis.

Authors:  L M Weigel; G J Anderson; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

10.  Prevalence of Quinolone Resistance in Enterobacteriaceae from Sierra Leone and the Detection of qnrB Pseudogenes and Modified LexA Binding Sites.

Authors:  Tomasz A Leski; Michael G Stockelman; Umaru Bangura; Daniel Chae; Rashid Ansumana; David A Stenger; Gary J Vora; Chris R Taitt
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.